Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
暂无分享,去创建一个
A. Torbicki | G. Simonneau | M. Hoeper | M. Kurzyna | B. Degano | D. Bonderman | I. Lang | R. Giorgino | M. Delcroix | N. Galiè | K. Karlócai | Michela Efficace | M. Efficace
[1] H. Ghofrani,et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. , 2010, American journal of respiratory and critical care medicine.
[2] K. Mubarak. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. , 2010, Respiratory medicine.
[3] G. Filippatos,et al. Guidelines for the diagnosis and treatment of pulmonary hypertension , 2009 .
[4] H. Ghofrani,et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.
[5] R. White. Update on the Development of Oral Prostacyclin Analogs for the Treatment of PAH , 2009 .
[6] K. Kosugi,et al. A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl) , 2008, Journal of Pharmacology and Experimental Therapeutics.
[7] G. Simonneau,et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.
[8] K. Kosugi,et al. A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl) , 2008, Journal of Pharmacology and Experimental Therapeutics.
[9] J. Hwa,et al. New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues , 2007, British journal of pharmacology.
[10] Tetsuhiro Yamada,et al. 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug , 2007, Journal of Pharmacology and Experimental Therapeutics.
[11] K. Kuwano,et al. 2- -N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug , 2007 .
[12] P. Collinson,et al. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? , 2005, European heart journal.
[13] R. Barst,et al. Prostanoid therapy for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[14] A. Branzi,et al. Prostanoids for Pulmonary Arterial Hypertension , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.
[15] T. Evans,et al. Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by human pulmonary artery smooth muscle cells: implications for pulmonary hypertension. , 2002, Molecular pharmacology.
[16] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[17] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[18] M. Humbert,et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.
[19] L. Rubin,et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. , 2002, American journal of respiratory cell and molecular biology.
[20] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[21] S. Rich,et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.
[22] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[23] B. Groves,et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.
[24] J. Vane,et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.